PSG Stock Overview
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany.
PharmaSGP Holding SE Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€18.70|
|52 Week High||€29.60|
|52 Week Low||€17.70|
|1 Month Change||-6.50%|
|3 Month Change||-20.76%|
|1 Year Change||-26.67%|
|3 Year Change||-15.77%|
|5 Year Change||n/a|
|Change since IPO||-45.80%|
Recent News & Updates
PharmaSGP Holding SE Just Beat Revenue Estimates By 25%Dec 02
One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts DramaticallyFeb 16
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings PotentialJan 26
Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?Dec 04
|PSG||DE Pharmaceuticals||DE Market|
Return vs Industry: PSG matched the German Pharmaceuticals industry which returned -26.5% over the past year.
Return vs Market: PSG underperformed the German Market which returned 5.7% over the past year.
|PSG Average Weekly Movement||5.1%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||5.0%|
|10% most volatile stocks in DE Market||9.4%|
|10% least volatile stocks in DE Market||2.3%|
Stable Share Price: PSG is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PSG's weekly volatility (5%) has been stable over the past year.
About the Company
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for treatment of hair loss; Dorisol, a pain relies tablet; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten, for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness and mood swings; Deruba, a cream for skin redness; Lentisol prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.
PharmaSGP Holding SE Fundamentals Summary
|PSG fundamental statistics|
Is PSG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PSG income statement (TTM)|
|Cost of Revenue||€9.16m|
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
|Earnings per share (EPS)||1.25|
|Net Profit Margin||15.37%|
How did PSG perform over the long term?See historical performance and comparison